media – Page 571 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Augmented Reality software lets doctors see under patients’ skin

Scientists from the University of Alberta have unveiled ProjectDR, technology that uses augmented reality (AR) to display medical images such as CT and MRI scans directly onto a patient’s body.
- Source: medicaldevice-network
- 460
- January 26, 2018
augmented reality CT and MRI scans Researches
AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.
- Source: finance.yahoo
- 678
- January 26, 2018
cancer inhibitor New Approvals ovarian
Tmunity nabs $100M for next-gen T-cell immunotherapies

Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
- Source: fiercebiotech
- 505
- January 26, 2018
blood cancer Series solid tumor T-cell therapies
Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S.
- Source: finance.yahoo
- 534
- January 26, 2018
Gene therapy Market Views voretigene neparvovec
Emergency medical devices and equipment for every office

Accidents happen and emergencies arise in every office and in every industry and being prepared for situations such as these is vital.
- Source: Ddu
- 743
- January 26, 2018
Ddu College Emergency medical devices
York County sues 25 opioid manufacturers, distributors

With opioid-overdose deaths skyrocketing as 2017 comes to a close, York County is suing more than two dozen drug companies that "have intentionally misled the public about the dangers of opioids."
- Source: Yorkdispatch
- 597
- January 25, 2018
opioid polices
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

The commercial life for Novartis’ Arzerra outside the U.S. is coming to an end.
- Source: Fiercepharma
- 544
- January 25, 2018
Arzerra CLL Company Insight
Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain.
- Source: Ddu
- 42,735
- January 25, 2018
Ddu College Peptic ulcers
Boosting cancer therapy with cross-dressed immune cells

Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. Immunotherapies are breakthrough treatments that stimulate the patient’s immune cells to attack the tumor through the recognition of aberrant molecules called tumor antigens. They can be very effective, but currently can only cure a minority of patients with solid tumors. Researchers and physicians are now looking into ways of increasing the precision and strength of the immune attack on the tumor. Dendritic cell vaccines One approach is the “dendritic cell vaccine”. Dendritic cells are specialized immune cells whose role is to capture antigens from foreign bodies and present them to the immune system’s killer T cells, which will then attack and destroy the invaders. For the vaccine, dendritic cells are taken out of the patient, “force-fed” with tumor antigens, and finally re-injected back into ...
- Source: medicalxpress
- 585
- January 25, 2018
artificial molecules cancer tumor immunotherapies Researches
Amgen Jumps as Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. On Monday, the company revealed Phase IIIb data that demonstrated the drug is also effective in reducing the number of episodic headaches in patients who have not responded to previous treatments.
- Source: biospace
- 616
- January 25, 2018
Aimovig Amgen Clinical Trials episodic headaches migraine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.